These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12877083)

  • 21. Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.
    Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder RE; Marx N; Sliwa K; Weber MA; Williams B; Yusuf S
    Eur Heart J; 2019 Jul; 40(25):2032-2043. PubMed ID: 30919899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin I-converting enzyme inhibitor improves reactive hyperemia in elderly hypertensives with arteriosclerosis obliterans.
    Okuro M; Morimoto S; Takahashi T; Okaishi K; Nakahashi T; Murai H; Iwai K; Kanda T; Matsumoto M
    Hypertens Res; 2006 Sep; 29(9):655-63. PubMed ID: 17249520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The HOPE Study (Heart Outcomes Prevention Evaluation).
    Sleight P
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Arteriosclerosis obliterans in young women.
    Holmes DR; Burbank MK; Fulton RE; Bernatz PE
    Am J Med; 1979 Jun; 66(6):997-1000. PubMed ID: 453230
    [No Abstract]   [Full Text] [Related]  

  • 26. Management of cardiovascular risk in diabetic patients: evolution or revolution?
    Ceriello A; Sechi LA
    Diabetes Nutr Metab; 2002 Apr; 15(2):121-7. PubMed ID: 12059094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Renin-angiotensin system blockade reduces cardiovascular mortality and morbidity attributable to arterial hypertension by primary and secondary prevention. The end of the road?].
    Coca A; Ruilope LM
    Med Clin (Barc); 2000 Jul; 115(5):178-80. PubMed ID: 10996874
    [No Abstract]   [Full Text] [Related]  

  • 28. [Angiotensin converting enzyme inhibitors in arterial hypertension].
    Ramón González-Juanatey J
    Rev Esp Cardiol; 1999; 52 Suppl 3():73-8. PubMed ID: 10614152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine.
    Ball SG; White WB
    Am J Cardiol; 2003 May; 91(10A):15G-21G. PubMed ID: 12781904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of patients with hypertension and diabetes mellitus: advances in the evidence for intensive treatment.
    White WB; Prisant LM; Wright JT
    Am J Med; 2000 Feb; 108(3):238-45. PubMed ID: 10723978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
    Gaede P; Vedel P; Larsen N; Jensen GV; Parving HH; Pedersen O
    N Engl J Med; 2003 Jan; 348(5):383-93. PubMed ID: 12556541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study.
    Zidek W; Schrader J; Lüders S; Matthaei S; Hasslacher C; Hoyer J; Zemmrich C; Bramlage P; Sturm CD; Paar WD
    Cardiovasc Diabetol; 2012 Jan; 11():1. PubMed ID: 22230104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of cardiovascular disease: an evidence-based clinical aid 2004.
    Fulcher GR; Amarena JV; Conner GW; Gilbert RE; Hankey GJ;
    Med J Aust; 2004 Sep; 181(S6):S1-S14. PubMed ID: 15377260
    [No Abstract]   [Full Text] [Related]  

  • 34. Perindopril for control of blood pressure in patients with hypertension and other cardiovascular risk factors: an open-label, observational, multicentre, general practice-based study.
    Ogilvie RI; Anand S; Roy P; De Souza S;
    Clin Drug Investig; 2008; 28(11):673-86. PubMed ID: 18840010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors in arterial occlusion of the limbs.
    Widmer LK; Hartmann G; Duchosal F; Piechl SC
    Ger Med Mon; 1969 Oct; 14(10):476-9. PubMed ID: 5364343
    [No Abstract]   [Full Text] [Related]  

  • 36. The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results.
    Hansson L; Zanchetti A
    Blood Press; 1994 Sep; 3(5):322-7. PubMed ID: 7866597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.
    Gerstein HC
    Diabetes Metab Res Rev; 2002; 18 Suppl 3():S82-5. PubMed ID: 12324991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A FOLLOW-UP STUDY ON AUTOLOGOUS BONE MARROW MONONUCLEAR CELLS TRANSPLANTATION FOR CRITICAL LOWER ARTERIOSCLEROSIS OBLITERANS IN DIABETIC PATIENTS].
    Dou Y; Zhao J; Zhang L; Wang X; Yuan H; Yuan C
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2015 Jul; 29(7):893-8. PubMed ID: 26540987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Incidence of hyperlipemia, hyperuricemia, diabetes mellitus, hypertension and overweight in arterial obliterating disease].
    Wollenweber J; Doenecke P; Greten H; Hild R; Nobbe F; Schmidt FH; Wagner E
    Dtsch Med Wochenschr; 1971 Jan; 96(3):103-7. PubMed ID: 5539511
    [No Abstract]   [Full Text] [Related]  

  • 40. The association between retinopathy, nephropathy, cardiovascular disease and long-term metabolic control in type 1 diabetes mellitus: a 5 year follow-up study of 442 adult patients in routine care.
    Agardh CD; Agardh E; Torffvit O
    Diabetes Res Clin Pract; 1997 Mar; 35(2-3):113-21. PubMed ID: 9179466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.